GMAB
HOLD
Conviction: 2/5
$20B
Genmab A/S
Investment Thesis
Danish antibody pioneer transitioning from royalty collector (83% of rev) to integrated biotech. DARZALEX royalties ($3.1B, 18-20% of J&J $14.3B net sales) are the cash engine. Epkinly ($468M, +67%) is the growth driver — EPCORE DLBCL-2 in 1L DLBCL could expand TAM 5-6x. Acquired Merus ($8B) for petosemtamab (HNSCC, 2 BTDs) and ProfoundBio ($1.8B) for Rina-S (FRa ADC, PROC). 2026 = catalyst-rich: up to 6 registrational readouts. Key risk: DARZALEX US LOE ~2029.
Bull Case
Epkinly peak sales exceed $3B in lymphoma. Petosemtamab delivers $1B+ in H&N cancer. Darzalex royalties remain strong through 2029 LOE. Platform generates additional partnerships and royalties.
Bear Case
Darzalex US LOE in 2029 creates revenue cliff. Epkinly faces competition from other CD20 bispecifics. Merus acquisition proves overpriced. Partner-dependent model limits value capture.
Drug Portfolio (13)
Oncology
Bispecific
IV/SC
Hematology
Bispecific antibody
SC
| Drug | Stage | Role | Ownership | Area | Modality |
|---|
| Tivdak | APPROVED | CO_DEVELOPER | 50% | Oncology | ADC |
| Rina-S | PHASE3 | CO_DEVELOPER | 50% | Oncology | ADC |
| Bizengri | APPROVED | LICENSEE | 100% | Oncology | Bispecific antibody |
| Amlenetug | PHASE3 | ORIGINATOR | 0% | Neurology | Antibody |
Financials (USD)
| Period | Revenue ($M) | Gross Margin | R&D | SG&A | Op Income | Op Margin | Net Income | EPS |
|---|
| 2024A | $3,121 | — | $0 | $0 | $0 | — | $0 | — |
| 2025A | $3,720 | 93.6% | $0 | $0 | $1,263 | 34.0% | $0 | — |
| 2026E | $4,230 | — | $0 | $0 | $1,150 | 27.2% | $0 | — |
| 2027E | $4,800 | — | $0 | $0 | $0 | — | $0 | — |
| 2028E | $5,200 | — | $0 | $0 | $0 | — | $0 | — |
Recent Quarters
| Quarter | Revenue ($M) | Gross Margin | Op Margin | EPS |
|---|
| Q4 2025 | $938 | 94.3% | 25.9% | $2.50 |
| Q3 2025 | $1,072 | 94.2% | 40.8% | $6.50 |
| Q2 2025 | $875 | 94.3% | 36.6% | $4.20 |
| Q1 2025 | $715 | 94.4% | 35.0% | $3.30 |
Catalysts (10)
Darzalex - MM - Bispecific Combo Data
CLINICAL
Genmab JPM 2026 Presentation
2026
Rybrevant - NSCLC - SC Formulation Data
CLINICAL
Genmab JPM 2026 Presentation
H1 2026
GMAB - Merus Integration Update
CORPORATE
Genmab JPM 2026 Presentation
Q2 2026
Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN2)
CLINICAL
SM
Genmab-Merus acquisition press release Sep 29, 2025; FDA BTD designations
H2 2026
Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN1)
CLINICAL
SM
FDA BTD designation; Genmab FY2025 earnings call Feb 17, 2026
H2 2026
Rina-S - PROC - Ph2 - Data Update (RAINFOL-01)
CLINICAL
SM
ClinicalTrials.gov NCT05579366
H2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)
CLINICAL
SM
NCT05578976; EPCORE NHL-2 ASH 2024 (Blood 2024;144:581); POLARIX 5-year JCO 2025
H2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)
CLINICAL
SM
Genmab JPM 2026 Presentation
H2 2026
Petosemtamab - HNSCC - BLA Filing
REGULATORY
SM
Genmab JPM 2026 Presentation
H1 2027
Rina-S - PROC - Accelerated Approval Filing
REGULATORY
SM
Genmab JPM 2026 Presentation
Q1 2027
Open Debates (4)
Underappreciated Risk: Darzalex US LOE 2029 — Royalty Cliff
Bull
Darzalex is a biologic — biosimilar erosion is slower than small molecule generics. SubQ formulation (Darzalex Faspro) may retain share. New products diversify the royalty base.
Bear
Darzalex is $14.4B and generates ~$2.2B in royalties for Genmab — approximately 50% of total royalty income. Even with slower biosimilar erosion, a 40-50% decline over 3 years post-LOE means $800M-1.1B in lost annual royalties. That is existential for a company Genmab's size. The replacement assets (Epkinly, petosemtamab) are years from generating comparable royalties.
Conviction: 5/5
Was the 8B Merus acquisition justified?
Bull
2 BTDs, multi-billion peak, 2027 launch. LGR5 pathway validated. NPV 10-15B if works. Triclonics platform.
Bear
Novel mechanism unvalidated in randomized setting. 8B write-off risk if fails.
Conviction: 2/5
Would change view: Ph3 interim: efficacy boundary crossed = conviction 4. Futility = conviction 1.
Underappreciated Growth Driver: Rybrevant (amivantamab) Royalty Upside
Bull
Rybrevant hit $2.8B in 2025 and is still growing — becoming the standard-of-care bispecific in EGFR-mutated NSCLC. Genmab earns royalties on all J&J antibody-based drugs using its technology. As Rybrevant scales, the royalty contribution compounds quietly. Combined with Darzalex ($14.4B), Tecvayli ($1.5B), and Talvey ($800M), Genmab's J&J royalty stream is approaching $3B+/year — with limited opex required.
Bear
Royalties are lower margin than own-product revenue in terms of multiple. Genmab is dependent on J&J's commercial execution. Darzalex LOE 2029 will eventually erode the largest single stream.
Conviction: 5/5
Can Epkinly replace DARZALEX royalties before LOE?
Bull
Epkinly 1L DLBCL + FL + petosemtamab HNSCC = $5B+ owned product rev by 2030. Replaces DARZALEX. Multiple expansion.
Bear
DLBCL-2 fails. Epkinly niche $1.5B. Petosemtamab unproven. 60%+ revenue cliff from DARZALEX LOE.
Conviction: 3/5
Would change view: EPCORE DLBCL-2: PFS HR <0.75 = conviction 4-5. HR >0.85 = conviction 1-2.
Data from Supabase · Updated 2026-03-24